<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) June 9, 1997
------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
- ------------------------------------------ ------ ------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ------------------------------------------ -----------------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
On June 9, 1997, Boston Life Sciences, Inc. announced that its stockholders
approved a ten-for-one reverse split of its common stock at the Company's Annual
Meeting on June 6, 1997. The reverse split will become effective as of 5:00
p.m. today, and will reduce the number of common shares outstanding from
approximately 125 million to approximately 12.5 million. In addition, the
conversion rate for the preferred stock will similarly be adjusted on a ten-for-
one basis.
The Company indicated that the reverse split should result in a broader market
for the stock than that which currently exists. Also, as a result of the split,
the Company will seek a listing on NASDAQ's more visible National Market rather
than the SmallCap Market where the stock is currently listed.
BLSI is engaged in the research and development of novel therapeutics for
cancer, autoimmune disease, and central nervous system disorders.
Item 7. Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated June 9, 1997.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: June 12, 1997 By:/s/ Joseph Hernon
------------------
Joseph Hernon
Chief Financial Officer
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- ----------- ----
99.1 Press Release, dated June 9, 1997 5
<PAGE>
Exhibit 99.1
BOSTON LIFE SCIENCES STOCKHOLDERS APPROVE
------------------------------------------
TEN-FOR-ONE REVERSE SPLIT OF COMMON STOCK
-----------------------------------------
Boston, MA, June 9, 1997 - Boston Life Sciences, Inc. (NASDAQ: BLSI) announced
that its stockholders approved a ten-for-one reverse split of its common stock
at the Company's Annual Meeting on June 6, 1997. The reverse split will become
effective as of 5:00 p.m. today, and will reduce the number of common shares
outstanding from approximately 125 million to approximately 12.5 million. In
addition, the conversion rate for the preferred stock will similarly be adjusted
on a ten-for-one basis.
David Hillson, the Company's Chairman and Chief Executive Officer stated, "We
believe that the reverse split will result in a broader market for the stock
than that which currently exists. Also, as a result of the split, the Company
will seek a listing on NASDAQ's more visible National Market rather than the
SmallCap Market where the stock is currently listed."
The effects of the reverse stock split may vary materially from expectations.
BLSI is engaged in the research and development of novel therapeutics for
cancer, autoimmune disease, and central nervous system disorders. BLSI's
products in clinical trials or in pre-clinical development include the above
mentioned Altropane; Troponin I, an anti-angiogenesis factor for the treatment
of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system
growth factor; THERAFECTIN for the treatment of rheumatoid arthritis; and two
transcription factors to control the expression of molecules associated with
autoimmune disease and allergies.
For additional information contact:
Joseph Hernon
Chief Financial Officer
(617) 425-0200
